Pulmonx Corporation (NASDAQ:LUNG) Receives Average Rating of “Hold” from Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has been given a consensus rating of “Hold” by the ten ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $6.8071.

Several equities research analysts have issued reports on LUNG shares. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a report on Friday. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. Finally, Lake Street Capital cut their price target on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th.

Hedge Funds Weigh In On Pulmonx

A number of large investors have recently added to or reduced their stakes in LUNG. R Squared Ltd bought a new stake in shares of Pulmonx in the second quarter valued at about $41,000. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in Pulmonx in the 2nd quarter valued at approximately $197,000. Bank of Montreal Can acquired a new stake in Pulmonx in the 2nd quarter valued at approximately $53,000. Corton Capital Inc. bought a new stake in Pulmonx in the 2nd quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new position in Pulmonx during the 2nd quarter worth approximately $84,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Trading Up 6.0%

Shares of NASDAQ LUNG opened at $1.51 on Monday. Pulmonx has a twelve month low of $1.31 and a twelve month high of $9.35. The stock has a market cap of $62.08 million, a price-to-earnings ratio of -1.07 and a beta of 0.07. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62. The company’s fifty day moving average is $1.92 and its 200-day moving average is $1.79.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.